Jihua Group(601718)
Search documents
际华集团(601718) - 际华集团第六届董事会第十七次会议决议公告
2026-03-17 10:15
证券代码:601718 证券简称:际华集团 公告编号:临 2026-005 际华集团股份有限公司 第六届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 际华集团股份有限公司(以下简称"公司")第六届董事会第十七次会议于 2026 年 3 月 13 日召开,会议采取通讯表决方式进行。应出席会议的董事 8 人, 实际出席会议的董事 8 人。会议按照会议通知所列议程进行,会议召集、出席会 议董事人数、召开程序等符合有关法律法规和公司章程规定。会议经审议,形成 如下决议: 一、审议通过关于《2026 年度投资计划》的议案 表决结果:8 票同意、0 票弃权、0 票反对。 同意公司 2026 年度投资计划,投资总额 75,770 万元,其中固定资产投资 51,182 万元,股权投资 24,588 万元。 二、审议通过关于《向新疆际华服装科技有限公司增资》的议案 表决结果:8 票同意、0 票弃权、0 票反对。 同意公司以自有资金向全资子公司新疆际华服装科技有限公司增资 7,800 万元,授权经理层办理增资相关手续 ...
际华集团(601718) - 际华集团关于与关联方共同投资设立合资公司暨关联交易的进展公告
2026-03-03 10:00
证券代码:601718 证券简称:际华集团 公告编号:临 2026-004 际华集团股份有限公司 名称:新兴际华集团供应链有限公司 类型:其他有限责任公司 法定代表人:刘涛 关于与关联方共同投资设立合资公司 暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 际华集团股份有限公司(以下简称"公司")于 2026 年 1 月 19 日召开第六届 董事会第十六次会议,审议通过了关于《与关联方共同投资设立合资公司暨关联 交易》的议案,同意与新兴际华集团有限公司(以下简称"新兴际华集团")、 新兴铸管股份有限公司(以下简称"新兴铸管")共同投资设立新兴际华供应链 有限公司(以下简称"供应链公司"),新设公司注册资本 5 亿元人民币,其中 公司出资人民币 12,500 万元,持有供应链公司注册资本的 25%;新兴际华集团 出资人民币 20,000 万元,持有供应链公司注册资本的 40%;新兴铸管出资人民 币 17,500 万元,持有供应链公司注册资本的 35%。具体详见公司于 2026 年 1 月 21 日在上海证券交 ...
海南海药:关于与新兴际华集团财务有限公司签署《金融服务协议》的公告

Zheng Quan Ri Bao Zhi Sheng· 2026-02-25 14:09
Core Viewpoint - Hainan Haiyao announced the renewal of the financial service agreement with Xinxing Jihua Group Financial Co., Ltd., which will be effective from April 23, 2026, to April 22, 2029 [1] Financial Agreement Details - The maximum daily deposit balance for the company and its subsidiaries at the financial company will not exceed 1 billion yuan [1] - The total comprehensive credit line provided by the financial company to the company will also be capped at 1 billion yuan [1]
海南海药:控股股东变更同业竞争承诺期限至2年内解决
Xin Lang Cai Jing· 2026-02-25 12:43
Core Viewpoint - Hainan Haiyao announced that it received a letter from its controlling shareholders, Xinxing Jihua Group Co., Ltd. and Xinxing Jihua Pharmaceutical Holdings Co., Ltd., regarding the extension of the commitment period to resolve competition issues with Xinxing Lingyun Pharmaceutical Chemical Co., Ltd. and Tianjin Huajin Pharmaceutical Co., Ltd. [1] Group 1 - The original commitment to resolve the competition issues was set to expire on February 24, 2025, but has now been extended by two years [1] - The controlling shareholders had previously committed to resolving the competition issues within one year from the original deadline [1] - The extension is attributed to historical legacy issues, profitability concerns, and the complexity of audit evaluations and related procedures [1]
际华集团:公司当前应急生产任务均正常、高效开展
Zheng Quan Ri Bao Wang· 2026-01-30 15:10
Core Viewpoint - Jihua Group (601718) is currently conducting its emergency production tasks normally and efficiently, ensuring smooth operations and financial stability [1] Group 1 - The company has confirmed that all emergency production tasks are being carried out effectively [1] - The financial structure of the company is stable, and the use of funds is compliant [1] - The company is fully committed to ensuring the smooth progress of its production and operations [1]
际华集团:公司将在年报披露期末股东人数
Zheng Quan Ri Bao Wang· 2026-01-30 11:42
Group 1 - The company, Jihua Group (601718), will disclose the number of shareholders as of the end of the reporting period in its annual report [1]
际华集团:公司高度重视市值管理工作
Zheng Quan Ri Bao Wang· 2026-01-30 10:46
Group 1 - The company emphasizes the importance of market value management and has developed relevant management systems and work plans [1] - The company aims to actively maintain its market value by improving operational quality, standardizing corporate governance, enhancing information disclosure, and strengthening communication with investors [1]
际华集团:公司管理层始终高度重视公司的经营与发展
Zheng Quan Ri Bao Wang· 2026-01-30 10:40
Group 1 - The company management emphasizes the importance of business operations and development [1] - The company will continue to focus on its core business and strengthen its competitive advantages [1] - The company is committed to promoting high-quality development and aims to reward investors' trust and support [1]
际华集团:公司现有外骨骼产品可解决部分人群的相关需求,针对特殊功能需求可提供定制开发服务
Zheng Quan Ri Bao Wang· 2026-01-30 10:40
Core Viewpoint - The company is focusing on customized development services for exoskeleton products to meet specific functional needs, primarily targeting large clients in government, enterprises, and research institutions through standardized order models [1] Group 1 - The company currently offers exoskeleton products that address certain needs of specific populations [1] - Customized development services are available for special functional requirements [1] - The company is not currently open to individual retail or small order sales channels [1] Group 2 - The company primarily utilizes public bidding and directed bidding for standardized order models [1] - The focus is on large-scale cooperation demands in specialized fields [1]
际华集团:稀贝斯产品已经通过国家有关部门的检测,当前已进入批量生产阶段
Zheng Quan Ri Bao Wang· 2026-01-30 10:40
Group 1 - The core point of the article is that Jihua Group (601718) has confirmed that its product, Xibeisi, has passed national testing and is now in mass production [1] Group 2 - Jihua Group responded to investor inquiries on an interactive platform regarding the status of its Xibeisi products [1] - The company is moving forward with the production phase after receiving the necessary approvals from relevant national departments [1]